909718-11-2

Basic information

• Product Name: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4-acetyl-2-cyclopropyl-, phenylmethyl ester
• CAS NO: 909718-11-2
• Molecular Formula: C20H18N2O3
• Molecular Weight: 334.375
• Mol File: 909718-11-2.mol

Chemical Properties

• CAS DataBase Reference: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4-acetyl-2-cyclopropyl-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4-acetyl-2-cyclopropyl-, phenylmethyl ester(909718-11-2)
• EPA Substance Registry System: Pyrazolo[1,5-a]pyridine-3-carboxylic acid, 4-acetyl-2-cyclopropyl-, phenylmethyl ester(909718-11-2)

Safety Data

• Hazardous Substances Data: 909718-11-2(Hazardous Substances Data)

Upstream product

• 909717-93-7 benzy 2-cyclopropyl-4-(1-hydroxyethyl)pyrazolo[1,5-a]pyridine-3-carboxylate 

Relevant articles and documents

Phosphodiesterase inhibitors. Part 4: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. Here we show that a 4,4-dimethylpyrazolone subunit serves as an effective surrogate for the 5-methyl-4,5-dihydropyridazin-3(2H)-one ring of KCA-1490 whilst lacking a stereogenic centre. The 2- and 7-substituents in the pyrazolo[1,5-a]pyridine subunit markedly influence the PDE-inhibitory profile and can be adjusted to afford either potent PDE4-selective inhibitors or dual PDE3/4 inhibitors. A survey of bicyclic heteroaromatic replacements for the pyrazolo[1,5-a]pyridine allowed further refinement of the inhibitory profile and identified 3-(8-methoxy-2-(trifluoromethyl)imidazo[1,2-a]pyridin-5-yl)-4, 4-dimethyl-1H-pyrazol-5(4H)-one as an orally active, achiral KCA-1490 analog with well-balanced dual PDE3/4-inhibitory activity.

Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient

Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).